Ondofren

Quick links to important sections

Ondofren

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Ondofren

Quick Facts

Property Description
Active ingredient Ondansetron (typically as hydrochloride)
Forms Oral tablets, Oral solution, Solution for injection
Pharmacological class Selective serotonin 5-HT3 receptor antagonist
General purpose Prevention and treatment of nausea and vomiting
Origin Synthetic compound

What Type of Medicine is Ondofren?

Ondofren is the trade name for the synthetic compound Ondansetron, which is classified as a highly selective antiemetic drug and is supplied as a prescription medicine. Its definitive pharmacological class is that of a selective serotonin 5-HT3 receptor antagonist. This specialized classification is clinically recognized for its targeted efficacy against sickness, positioning Ondansetron as a foundational therapeutic agent in managing the emetic reflex.

Composition and Available Forms of Ondofren

The core active ingredient in this medication is Ondansetron, typically formulated as the hydrochloride salt, defining the product as a single active ingredient product. Ondofren is intentionally manufactured across several pharmaceutical preparations to ensure flexibility in its route of administration, including the Oral route and the Intravenous (IV) route. Common drug forms include oral tablets, orally disintegrating tablets (ODT), and a solution for injection. The composition utilizes either an aqueous solution base for liquid forms or solid excipients for the tablet forms.

What is the General Purpose of Ondofren?

The general purpose of Ondofren is to provide foundational antiemetic therapy dedicated to the prevention and treatment of the feeling of nausea and the reflex of vomiting. It fulfills this function by disrupting the emetic stimuli transmission pathway. The drug's highly selective action of blocking the serotonin 5-HT3 receptor stops these chemical messengers from initiating the sickness response, establishing it as a primary prophylactic use compound when symptoms are anticipated.

Regulatory References

  1. Ondansetron Drug Label (FDA)

What side effects are possible with Ondofren?

Possible side effects and safety information

Official regulatory documents classify the safety profile of Ondofren (Ondansetron) by the frequency of observed adverse reactions and the physiological system affected. The most frequently documented side effects are typically non-serious events related to the central nervous system and the digestive tract.

Classification Examples of Documented Adverse Reactions
Very Common Headache
Common Constipation, Sensation of warmth or flushing, Local injection site reactions (for intravenous form)
Uncommon Arrhythmias, Bradycardia, Seizures, Movement disorders (e.g., dystonia), Asymptomatic increases in liver function tests
Rare QTc prolongation, Hypersensitivity reactions, Transient visual disturbances

The safety labeling highlights the potential for serious adverse reactions involving the Cardiac System. These include the risk of QT interval prolongation and the serious ventricular arrhythmia known as Torsade de Pointes, a risk officially documented as dose-dependent. Other serious reactions noted include severe hypersensitivity reactions (such as anaphylaxis) and the potential for Serotonin Syndrome when used with other serotonergic medicines.

Specific population safety considerations are formally documented. Patients with severe hepatic impairment require a specific dose restriction due to the prolonged clearance of the medicine. Furthermore, the use of Ondofren is generally contraindicated in individuals with Congenital Long QT Syndrome due to the heightened risk of cardiac events. Official labeling also includes a specific restriction: the medicine is contraindicated for co-administration with apomorphine.

Overdose and Emergency Response

Overdose and When to Seek Help

Ondofren is the brand name for the active ingredient ondansetron. Taking a quantity significantly higher than the prescribed dose can lead to an overdose. There is no specific antidote available, and management of overdose relies on supportive care.

Overdose presentations documented in official sources related to this class of medication include visual disturbances, such as temporary loss of sight, severe or worsened constipation, and cardiovascular effects.

  • Cardiovascular manifestations may include irregular heartbeat, low blood pressure (hypotension) that can cause fainting or lightheadedness, and a temporary form of heart block.
  • Serotonin Syndrome, a potentially serious condition, has been reported following excessive ingestion, particularly in young children. Symptoms may involve rapid heartbeat (tachycardia), somnolence, agitation, confusion, stiffness, hyperreflexia, and seizure. These effects typically required immediate supportive care and resolved completely within one to two days.

When to Seek Immediate Medical Attention

If an overdose is suspected, or if symptoms such as sudden visual changes, chest pain, an irregular or very slow heartbeat, severe dizziness, seizures, or signs of confusion and agitation occur, seek emergency medical attention right away. Contacting a poison control center immediately is crucial. Patients with pre-existing heart conditions, especially those involving the heart's electrical activity (such as congenital long QT syndrome), are at increased risk of serious cardiovascular complications from an overdose.

Therapeutic Uses of Ondofren

This medicine is commonly used for providing symptomatic relief for antiemesis in specific clinical contexts.

Ondofren is generally applied as supportive care to address symptoms related to acute and anticipated nausea and vomiting stemming from chemotherapy (including both highly and moderately emetogenic regimens) and radiotherapy. Its use here supports patients during difficult episodes by easing distress and helps to ease the overall symptom burden.

The medication is relevant in perioperative settings for the prophylaxis and treatment of emesis and queasiness following general anesthesia and surgery. Providing timely symptomatic relief in this context assists with maintaining functional stability, contributing to easing strain that can be associated with surgical sites and supporting overall comfort. It is also commonly used to help manage severe, persistent vomiting in certain acute conditions where there is a risk of significant dehydration.

“This medication is considered relevant in settings marked by temporary physiological imbalance and contributes to easing the overall symptom load.”

Quick Fact: Relief for Acute Sickness
Primary Focus Nausea and Vomiting related to powerful external triggers.
Core Benefit Symptomatic relief to support patient comfort during acute episodes.
Typical Contexts Supportive care in oncology, and management during perioperative recovery.

Eligibility and Restrictions for Use

Who Can and Cannot Use Ondofren?

The eligibility for Ondofren (Ondansetron) is determined by official regulatory documents, which define specific population groups for whom use is allowed, restricted, or strictly prohibited.

Absolute Prohibitions

Ondofren must not be used in patients with a known hypersensitivity to the drug or those concurrently receiving Apomorphine, due to the risk of severe hypotension. Use is also contraindicated in patients with congenital long QT syndrome.

Age and Physiological Restrictions

Population Group Regulatory Status
Infants (CINV) Use is not established for chemotherapy-related sickness in children under 6 months of age.
Infants (PONV) Use is not established for postoperative sickness in children under 1 month of age.
Severe Hepatic Impairment Use is restricted; the total daily dose must not exceed 8 mg.
Pregnancy (First Trimester) Use is not recommended due to a suspected increased risk of orofacial malformations.
Breastfeeding Use is not recommended.

Eligibility rules confirm that adults and older adults are generally approved for use, though specific forms may be prohibited for patients with Phenylketonuria (PKU) or those with certain rare galactose intolerances.

What should I know about interactions with other medicines?

The regulatory documentation for Ondofren establishes specific, documented interaction patterns with other medicines and substances.

Mandatory Administration Restriction

Co-administration with the drug Apomorphine is formally contraindicated. This combination is prohibited by official regulatory authorities based on reports of profound hypotension and loss of consciousness documented in the prescribing information.

Pharmacokinetic Interactions

The clearance of Ondofren can be significantly affected by other drug types. The medicine is primarily cleared via multiple hepatic enzymes, including CYP3A4. Co-administration with potent CYP enzyme inducers such as Phenytoin, Carbamazepine, and Rifampicin is officially documented to cause a major reduction in Ondofren plasma concentrations and systemic exposure (AUC and Cmax) by increasing drug clearance. Severe hepatic impairment is also noted in regulatory labels as a condition that significantly reduces the clearance of Ondofren, a population factor relevant to the profile of co-administered CYP inducers.

Pharmacodynamic Interactions

Certain combinations carry an additive pharmacodynamic risk documented by regulatory authorities. The concomitant use of Ondofren with other serotonergic agents (e.g., SSRIs or SNRIs) is officially associated with an increased risk of developing Serotonin Syndrome. Furthermore, taking Ondofren with other drugs that prolong the QT interval is documented to increase the risk of additive QT interval prolongation. Food consumption is noted to slightly enhance the oral bioavailability of Ondofren.

Mechanism of Action

How Ondofren Works: Mechanism of Action


Ondofren functions as a highly selective competitive antagonist of the Serotonin 5-HT3 receptor (5- HT3 receptor). Its primary molecular action is to bind to this receptor, preventing the neurotransmitter serotonin (5- HT) from activating it.

This blockade occurs at two critical sites involved in the emetic reflex: peripherally, on the vagal nerve afferent terminals in the gastrointestinal (GI) tract, and centrally, within the brainstem's Chemoreceptor Trigger Zone (CTZ). By simultaneously blocking the 5- HT3 receptors at both locations, the drug directly interrupts the neural transmission of pro-emetic signals to the Vomiting Center.

The resulting physiological consequence of this dual-site antagonism is the suppression of afferent neural signals and the inhibition of subsequent motor responses associated with emesis. This interference with 5- HT-mediated signal transduction modifies overactive physiological responses within the central and peripheral pathways.

Dosage and Administration Information

Ondofren (ondansetron) is administered through three officially approved routes: oral, intravenous (IV), and intramuscular (IM). Oral dosage forms include tablets, solution, and the orally disintegrating tablet (ODT). The method of use is strictly defined by the clinical context, and administration is fundamentally prophylactic, meaning the dose is scheduled to occur at a specific time before the triggering event.

Dosing and Timing

Official regimens specify the dose based on the severity of the expected nausea. For Highly Emetogenic Chemotherapy (HEC), a standard single oral dose of 24 mg is administered 30 minutes before treatment. In cases of Moderately Emetogenic Chemotherapy (MEC), the regimen begins with an 8 mg oral dose 30 minutes pre-chemo, followed by subsequent 8 mg maintenance doses twice daily (every 12 hours) for up to two days. For prevention of Postoperative Nausea and Vomiting (PONV), a single 4 mg IV or IM injection may be given.

Oral doses can be taken with or without food. For the injectable solution, IV doses exceeding 8 mg must be diluted in a compatible fluid and infused over a minimum of 15 minutes to comply with regulatory standards.

Population-Specific Use

A critical restriction applies to patients with severe hepatic impairment (Child-Pugh score of 10 or greater), where the total maximal daily dose must not exceed 8 mg. Conversely, official labeling specifies that no adjustment to the dosage or dosing frequency is required for older adult patients or those with renal impairment.

Recent Clinical Evidence

Research evidence / Overview of studies for Ondofren


Evidence for Use in Chemotherapy-Induced Nausea and Vomiting (CINV)

Research exploring CINV involves randomized controlled trials (RCTs) and meta-analyses that have examined adult and pediatric patients receiving emetogenic chemotherapy. Studies monitored outcomes related to physical discomfort, specifically the frequency of vomiting and the requirement for rescue medications in the acute phase (first 24 hours) and the delayed phase (subsequent days).

Findings describe patterns observed in these time intervals. Research has noted limited findings for monotherapy in delayed symptoms after highly emetogenic regimens, and studies have explored the use of a multi-drug approach in this context. Long-term effects are not fully established beyond the immediate post-treatment period.


Evidence for Use in Postoperative Nausea and Vomiting (PONV)

The research base for preventing sickness following surgery under general anesthesia consists of numerous clinical studies. These trials monitored outcomes related to episodic or acute changes in symptoms across defined time intervals, primarily focusing on the immediate and late recovery phases (up to 48 hours).

Research noted that the period of observation for sustained symptomatic control was limited. Additionally, studies provide limited insight into treating breakthrough symptoms (sickness that occurs despite initial prevention measures).


Evidence in Special Populations and Research Gaps

Studies have explored the compound's use in special populations, particularly pediatric patients (infants and children), across CINV and PONV settings. Currently, data for certain groups remain insufficient across all studied indications, and findings were observed only in the populations studied.

One key research limitation noted is that the current results apply only to the populations studied. Evidence quality varies across studies, and comparative evidence is sometimes lacking. Certainty remains low in some aspects, and research is ongoing to address these limitations.

Frequently Asked Questions (FAQ)

Common questions about Ondofren (FAQ)


Q: How long can a person typically take Ondofren?

Regulatory information indicates that Ondofren is primarily used for the prophylactic management of sickness associated with specific, acute events, such as chemotherapy or surgery. Official administration regimens describe its use for limited durations, typically for a period of one to two days. Regulatory documents note that studies establishing long-term effects are limited beyond the immediate post-treatment period.


Q: Are there any major diet restrictions while taking Ondofren?

Official labeling states the medicine can be taken with or without food. Although no specific food restrictions are mandated in the regulatory documents, regulatory information notes that alcohol consumption may potentially worsen some of the common side effects, such as headache or fatigue.


Q: What makes Ondofren different from similar medications?

Ondofren is officially defined by its highly specific action as a selective serotonin 5-HT3 receptor antagonist. This specialized mechanism involves blocking the serotonin 5-HT3 receptor. This distinguishes it from other types of antiemetic medicines that target different receptor pathways.


Q: Do studies show Ondofren helps with long-term recovery?

The clinical research base for this drug focuses mainly on the mathbfacute phases of care, such as the period immediately following chemotherapy or surgery. Regulatory documents note that mathbflong-term effects and its contribution to sustained recovery are not fully established beyond the immediate post-treatment follow-up period.


Q: Can Ondofren affect the results of lab tests?

Regulatory documents list asymptomatic increases in mathbfliver mathbffunction mathbftests mathbf(LFTs) as an uncommon reported side effect. Studies have also explored its effects on the metabolic clearance of certain medicines used for conditions like blood sugar management, suggesting a link to changes in these metabolic processes.


Q: Does Ondofren have to be taken at a specific time of day?

The official dosing is mathbfprophylactic, meaning the dose is scheduled to occur at a specific time mathbfbefore the event expected to cause sickness. Subsequent or maintenance doses are then scheduled at regular intervals, such as every 12 hours, regardless of the time of day.


Q: Is Ondofren a generic drug?

Ondofren is the brand name for the active ingredient, mathbfondansetron. Regulatory documentation confirms that this active ingredient is available in mathbfgeneric form.


Q: Can Ondofren make pre-existing conditions worse?

Official warnings note that the medicine is mathbfcontraindicated (must not be used) in patients with mathbfCongenital mathbfLong mathbfQT mathbfSyndrome. A specific dose restriction is also mandated for patients with mathbfsevere mathbfhepatic mathbfimpairment (liver issues).


Q: What kind of monitoring is needed while taking Ondofren?

Regulatory warnings recommend mathbfElectrocardiogram mathbf(ECG) mathbfmonitoring for patients who have pre-existing heart conditions, electrolyte imbalances (such as low potassium or magnesium), or who are taking other medicines known to prolong the QT interval.


Q: Why is Ondofren sometimes prescribed for a short period only?

The official indications and dosage schedules are primarily for the mathbfprophylactic (preventative) management of sickness associated with mathbfacute, time-limited clinical events, such as a course of chemotherapy or a surgical procedure. The duration of use is therefore tied to the timing of these events.


Q: How does Ondofren get processed by the body?

Regulatory information states that the medicine is extensively processed by the mathbfliver, primarily through mathbfhepatic mathbfmetabolism by various enzymes. A small percentage of the original dose, approximately mathbf10%, is excreted unchanged in the urine.


Q: How quickly does Ondofren start to work?

Regulatory information on the oral form indicates that the maximum concentration of the drug in the body is generally reached in approximately mathbf3 mathbfhours after administration.


Q: Can Ondofren be taken with common pain relievers like ibuprofen?

Official drug-drug interaction studies or regulatory summaries do mathbfnot mathbfreport mathbfa mathbfdirect, specific interaction between Ondofren and the common pain reliever ibuprofen.


Q: Is it common to feel tired when first starting Ondofren?

Yes, regulatory documents list mathbfmalaise/fatigue as a documented adverse reaction observed in mathbf5% or more of adult patients in clinical trials for chemotherapy-induced sickness.


Q: Can I drink alcohol while using Ondofren?

Official drug interaction data do mathbfnot mathbfreport mathbfa mathbfdirect chemical interaction between the drug and alcohol. However, regulatory information notes that consuming alcohol may potentially worsen some of the common side effects, such as headache or fatigue.


Q: Does Ondofren affect sleep patterns?

Regulatory adverse event reports note the occurrence of mathbfsomnolence (drowsiness or sleepiness) in patients. This is classified as a recognized adverse reaction, particularly in pediatric patients after surgery.


Q: What if I'm already taking a supplement? Can I still use Ondofren?

Regulatory labeling and patient information advise communicating the use of all products, including prescription, over-the-counter, and any mathbfsupplements, mathbfherbs, mathbfand mathbfvitamins. This is due to the potential for some of these products to influence the drug’s metabolism or increase the risk of side effects.


Q: What are the most common reasons someone would stop taking Ondofren?

Regulatory documents describe certain situations and signs where the medicine is mathbfnot mathbfrecommended or may need to be stopped. These include signs of mathbfhypersensitivity (allergic reaction), symptoms of mathbfSerotonin mathbfSyndrome, or in cases where there is a serious change in mathbfheart mathbfrhythm mathbf(QT mathbfprolongation).


Q: Are there different strengths of Ondofren available?

The medicine is available in various regulated strengths and forms, including oral tablets (e.g., mathbf4 mathbfmg, mathbf8 mathbfmg, mathbf24 mathbfmg), orally disintegrating tablets, an oral solution, and a solution for injection.


Q: Does Ondofren interact with caffeine?

Official drug interaction documents do mathbfnot mathbfreport mathbfa mathbfspecific mathbfchemical mathbfinteraction with caffeine.


Q: Is it normal to feel a change in appetite after starting Ondofren?

A mathbfloss mathbfof mathbfappetite is mentioned in regulatory documents as a possible symptom associated with a rare, serious adverse event related to bowel obstruction. It is not listed as a common, expected side effect in the general adverse reaction tables.


Q: Can men and women use Ondofren the same way?

While studies have explored differences in how the drug is metabolized between the sexes, official regulatory dosing instructions do mathbfnot mathbfspecify mathbfdifferent mathbfdosage mathbfadjustments for men and women.


Q: Does Ondofren have a black box warning?

Official regulatory labeling does mathbfnot mathbfinclude a formal mathbfBoxed mathbfWarning (the regulatory term for a “black box” warning).


Q: How long does Ondofren stay in the body after the last use?

The time it takes for the amount of drug in the plasma to be reduced by half (the half-life) is generally between mathbf3 mathbfand mathbf6 mathbfhours for the oral form.


Q: Are there any known interactions between Ondofren and herbal teas?

The official drug documents do mathbfnot list specific interactions with common herbal teas. However, regulatory patient information generally advises communicating the use of all mathbfherbs and supplements due to the potential for interaction.


Q: What percentage of people experience the most common side effects of Ondofren?

Regulatory adverse event tables note that common side effects such as headache, fatigue, constipation, and diarrhea were reported in mathbf5% mathbfor mathbfmore of adult patients when used for the prevention of chemotherapy-induced sickness.


Q: Is it safe to drive or operate machinery while taking Ondofren?

Because the medicine may cause adverse reactions such as mathbfdizziness or mathbfsomnolence mathbf(drowsiness), regulatory patient information recommends mathbfcaution regarding mathbfdriving mathbfor mathbfoperating mathbfmachinery, especially until a person is familiar with how the medicine affects them.


Q: Does Ondofren interact with birth control pills?

Official drug interaction summaries do mathbfnot mathbfreport mathbfa mathbfspecific mathbfchemical mathbfinteraction between the drug and common hormonal birth control methods.


Q: Does Ondofren have an effect on blood sugar levels?

While blood sugar changes are not listed in the main adverse event tables, regulatory research has noted effects on the metabolic clearance of certain medicines used for blood sugar management (metformin), which may influence these processes.


Q: Are there any known issues with fertility and Ondofren?

Non-human studies (animal reproductive toxicity studies) conducted as part of the regulatory review process did mathbfnot mathbfshow mathbfan mathbfincreased mathbfrisk mathbfof mathbfissues with fertility.


Q: Can Ondofren be taken with antacids?

Some ingredients found in common antacid medicines, such as magnesium, can cause imbalances in electrolytes (like low magnesium or potassium). Regulatory warnings state that these imbalances increase the risk of serious mathbfheart mathbfrhythm mathbfchanges when combined with Ondofren.

How should Ondofren be stored and disposed of?

Storage and Disposal Requirements for Ondansetron (Ondofren)

The storage of Ondansetron (Ondofren) is strictly defined by regulatory labeling to maintain stability.

️ Storage and Handling

Feature Requirement
Temperature Store at Controlled Room Temperature (20 C to 25 C/68 F to 77 F), allowing temporary excursions.
Protection Tablets must be protected from moisture. Liquid formulations must not be frozen.
Stability Diluted injection solution is stable for 48 hours at room temperature.
Child Safety Must be stored out of the sight and reach of children.

️ Disposal

Expired or unused Ondansetron must be disposed of according to local requirements and pharmaceutical waste handling instructions. Consult local authorities for specific guidelines on discarding medication safely.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Ondofren found in:

A-Z Index: